As of 2025-07-04, the Relative Valuation of CytomX Therapeutics Inc (CTMX) is 3.87 USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.48 USD, the upside of CytomX Therapeutics Inc based on Relative Valuation is 56.1%.
The range of the Relative Valuation is 3.07 - 5.41 USD.
| Range | Selected | |
| Trailing P/E multiples | 11.6x - 18.6x | 13.1x |
| Forward P/E multiples | 17.2x - 24.8x | 19.6x |
| Fair Price | 3.07 - 5.41 | 3.87 |
| Upside | 23.7% - 118.3% | 56.1% |
| Date | P/E |
| 2025-07-02 | 9.39 |
| 2025-07-01 | 8.94 |
| 2025-06-30 | 8.60 |
| 2025-06-27 | 8.52 |
| 2025-06-26 | 8.75 |
| 2025-06-25 | 8.37 |
| 2025-06-24 | 8.10 |
| 2025-06-23 | 8.18 |
| 2025-06-20 | 8.79 |
| 2025-06-18 | 7.99 |
| 2025-06-17 | 9.01 |
| 2025-06-16 | 9.32 |
| 2025-06-13 | 10.41 |
| 2025-06-12 | 11.32 |
| 2025-06-11 | 10.68 |
| 2025-06-10 | 10.22 |
| 2025-06-09 | 9.98 |
| 2025-06-06 | 10.00 |
| 2025-06-05 | 9.09 |
| 2025-06-04 | 9.50 |
| 2025-06-03 | 10.03 |
| 2025-06-02 | 9.50 |
| 2025-05-30 | 10.03 |
| 2025-05-29 | 9.54 |
| 2025-05-28 | 9.09 |
| 2025-05-27 | 8.05 |
| 2025-05-23 | 8.44 |
| 2025-05-22 | 8.07 |
| 2025-05-21 | 7.72 |
| 2025-05-20 | 7.80 |
| 2025-05-19 | 8.07 |
| 2025-05-16 | 7.69 |
| 2025-05-15 | 7.57 |
| 2025-05-14 | 9.01 |
| 2025-05-13 | 9.47 |
| 2025-05-12 | 8.07 |
| 2025-05-09 | 3.52 |
| 2025-05-08 | 4.13 |
| 2025-05-07 | 3.64 |
| 2025-05-06 | 3.66 |
| 2025-05-05 | 3.64 |
| 2025-05-02 | 3.04 |
| 2025-05-01 | 2.87 |
| 2025-04-30 | 2.82 |
| 2025-04-29 | 2.47 |
| 2025-04-28 | 2.68 |
| 2025-04-25 | 2.69 |
| 2025-04-24 | 2.90 |
| 2025-04-23 | 2.77 |
| 2025-04-22 | 2.79 |